This site is intended for Healthcare professionals only.

Dr Reddys out-licenses steroid DFD-06 to Encore Dermatology


Dr Reddys out-licenses steroid DFD-06 to Encore Dermatology

New Delhi: Drug major Dr Reddy’s Laboratories on Tuesday said it has out-licensed the future development, manufacturing and commercialisation rights of its topical high potency steroid DFD-06 to Encore Dermatology.

The drug is intended to be used for the treatment of moderate to severe plaque psoriasis.

“Under the terms of the agreement, Encore will be responsible for the commercialisation of DFD-05 in the United States,” Reddy’s Laboratories said in a regulatory filing.

Promius Pharma, a wholly owned subsidiary of Dr Reddy’s Laboratories, is eligible to receive certain pre and post commercialisation milestone payments of up to USD 32.5 million, followed by fixed royalty on net sales, it added.



Source: PTI
0 comment(s) on Dr Reddys out-licenses steroid DFD-06 to Encore Dermatology

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted